** Shares of Sinopharm Group 1099.HK rise 4.1% to HK$18.14, the biggest intraday pct gain since October 7
** Stock hits the highest point since April 23, snapping three straight session of losses, and is top pct gainer in the Hang Seng Index .HSI, which climbs 0.2%
** The Chinese pharmaceutical, healthcare products and medical devices distributor said its first-quarter net profit up 2.6% y/y at 1.46 billion yuan ($200.11 million) while revenue down 3.8% y/y at 141.7 billion yuan
** Citi keeps "buy" rating given Sinopharm's earnings growth potential from expectations of industry consolidation down the road, likely market share gain due to network expansion and less concern on finance costs
** Hang Seng Commerce & Industry Index .HSNC slips 0.2%, healthcare index .HSCIH falls 1.5%** Stock down 14.9% YTD
($1 = 7.2961 Chinese yuan)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。